Study of immune deficiency patients treated with subcutaneous immunoglobulin (IgPro20, Hizentra) on weekly and biweekly schedules

Trial Profile

Study of immune deficiency patients treated with subcutaneous immunoglobulin (IgPro20, Hizentra) on weekly and biweekly schedules

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Feb 2017

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Immunodeficiency disorders
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors CSL Behring
  • Most Recent Events

    • 30 Jan 2017 Planned End Date changed from 1 Aug 2017 to 1 Dec 2017.
    • 30 Jan 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Dec 2017.
    • 18 Oct 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top